𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combining endocrine agents with chemotherapy: Which patients and what sequence?

✍ Scribed by Kathleen I. Pritchard


Book ID
102109306
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
79 KB
Volume
112
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


In metastatic breast cancer, attempts to improve response to therapy by combining hormones and chemotherapy began in the 1970s. Since then, several randomized trials comparing single-agent hormone therapy or chemotherapy versus sequential combinations of these agents have been performed. In the majority of those studies, an increased response rate or an increased time to progression was observed when chemotherapy was added to hormone therapy or when hormone therapy was added to chemotherapy. However, in few of those trials was the increased response rate statistically significant or the response duration significantly prolonged, and no studies reported an improvement in overall survival. Furthermore, the studies did not make the correct comparisons of 1) hormone therapy alone followed by chemotherapy alone versus hormone therapy and chemotherapy given concurrently or 2) chemotherapy alone followed by hormone therapy versus concurrent chemotherapy and hormone therapy. To truly be advantageous, concurrent treatment should provide an increased response rate and response duration compared with the added or overall response rate and response duration of the same agents used sequentially. In the adjuvant setting, the timing and sequencing of hormone therapy and chemotherapy also has not been studied well. However, it has been accepted widely that adjuvant chemotherapy should be completed before beginning tamoxifen. No trials examining concurrent versus sequential treatment have been performed with hormone therapy and chemotherapy in the premenopausal setting or with aromatase inhibitors and chemotherapy in postmenopausal women. Considering the demonstrated importance of the timing of chemotherapy and tamoxifen in the postmenopausal setting, these questions should be explored further.


πŸ“œ SIMILAR VOLUMES


Single agent versus combination chemothe
✍ Rogerio C. Lilenbaum; Patricia Langenberg; Kay Dickersin πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

## Background: This meta-analysis was conducted to compare the effects of single agent versus combination chemotherapy on response rate, toxicity, and survival of patients with advanced nonsmall cell lung carcinoma (nsclc). ## Methods: The authors reviewed randomized clinical trials published in

Combined maintenance treatment of cancer